Conference
Pain palliation as an oncology label indication: Lessons learned in custirsen phase III development.
Abstract
222
Background: Durable pain palliation (dPP) in metastatic castrate-resistant prostate cancer (mCRPC) is a measure of clinical benefit suitable for a label indication. A randomized, double-blind, placebo-controlled, phase III study developed with FDA under a Special Protocol Assessment (SPA) compared custirsen/taxane (cust/tax) to placebo/taxane (plac/tax) as second-line chemotherapy for patients (pts) with mCRPC with disease …
Authors
Beer TM; Hotte SJ; De Bono JS; Beuzeboc P; Gabrail NY; Cain D; Jacobs C; Fizazi K
Volume
32
Pagination
pp. 222-222
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 1, 2014
DOI
10.1200/jco.2014.32.4_suppl.222
Conference proceedings
Journal of Clinical Oncology
Issue
4_suppl
ISSN
0732-183X